person · Reporting owner

Ben-Tzvi Avraham

Disclosed activity across 9 companies

Tapewire entity: 25914
SEC CIK: 0001944721

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Aterian, Inc.ATER · Entity 8078	Director	July 17, 2026	July 30, 2026
Bio Green Med Solution, Inc.CYCC · Entity 8225	Director	February 26, 2025	February 28, 2025
Black Titan CorpBTTC · Entity 8324	Director	October 01, 2025	March 19, 2026
CapForce Inc.OPGN · Entity 9776	Director	April 11, 2024	April 15, 2024
FiEE, Inc.MINM · Entity 7395	Director	September 26, 2024	October 02, 2024
Indaptus Therapeutics, Inc.INDP · Entity 6530	Director	December 23, 2025	January 23, 2026
LQR House Inc.LQR · Entity 8513	Director	October 16, 2024	October 23, 2024
Quantum Cyber N.V.QUCY · Entity 6633	Director	July 22, 2026	August 06, 2026
TITAN PHARMACEUTICALS INCTTNP · Entity 74432	Director	October 01, 2025	October 08, 2025

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Aterian, Inc.

Report date July 17, 2026 · Filed July 30, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	0	Reported balance Holding disclosure · report date 2026-07-17 · row 1 Holding and transaction disclosures are not merged. 1 source row Row 1 · Balance 0 F1: No shares of Common Stock are beneficially owned.

Filing footnotes · ownership attribution and instrument terms

F1: No shares of Common Stock are beneficially owned.

Bio Green Med Solution, Inc.

Report date February 26, 2025 · Filed February 28, 2025

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Non-Qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.33 · Expires 2035-02-26	Direct	700,000	Reported balance After 2025-02-26 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2025-02-26 · Grant · Acquired 700,000 · Balance 700,000 F1: On February 26, 2025 (the "Grant Date"), the Reporting Person was granted 700,000 Non-Qualified Stock Options to purchased shares of common stock (the "Common Stock") of Cyclacel Pharmaceuticals, Inc. (the "Company") in consideration of his services as a director of the Company. The option grant became exercisable on the Grant Date.

Filing footnotes · ownership attribution and instrument terms

F1: On February 26, 2025 (the "Grant Date"), the Reporting Person was granted 700,000 Non-Qualified Stock Options to purchased shares of common stock (the "Common Stock") of Cyclacel Pharmaceuticals, Inc. (the "Company") in consideration of his services as a director of the Company. The option grant became exercisable on the Grant Date.

Black Titan Corp

Report date October 01, 2025 · Filed March 19, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Ordinary Shares $0.001 par ValueSEC Table I · non-derivative	Direct	3,313	Reported balance Holding disclosure · report date 2025-10-01 · row 1 Holding and transaction disclosures are not merged. 1 source row Row 1 · Balance 3,313 F1: These shares were issued by Titan Pharmaceutical Inc.'s ("Titan"), and each share was exchanged for one share of Black Titan Corporation ("Black Titan") in connection with the business combination which closed on October 1, 2025 (the "Merger").
Options to purchase Ordinary SharesSEC Table II · derivative / convertible security	Direct	Not disclosed	Reported balance Holding disclosure · report date 2025-10-01 · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · Balance Not disclosed F2: Options issued pursuant to Titan's 2015 Omnibus Equity Incentive Plan with an exercise price equal to the closing price of Titan's common stock on August 15, 2022. These options were assumed by Black Titan in the Merger and exchanged for 1 Black Titan option for each Titan option.
Options to purchase Ordinary SharesSEC Table II · derivative / convertible security	Direct	Not disclosed	Reported balance Holding disclosure · report date 2025-10-01 · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · Balance Not disclosed F3: Options issued pursuant to Titan's 2015 Omnibus Equity Incentive Plan with an exercise price equal to the closing price of Titan's common stock on September 15, 2022. These options were assumed by Black Titan in the Merger and exchanged for 1 Black Titan option for each Titan option.

Filing footnotes · ownership attribution and instrument terms

F1: These shares were issued by Titan Pharmaceutical Inc.'s ("Titan"), and each share was exchanged for one share of Black Titan Corporation ("Black Titan") in connection with the business combination which closed on October 1, 2025 (the "Merger").

F2: Options issued pursuant to Titan's 2015 Omnibus Equity Incentive Plan with an exercise price equal to the closing price of Titan's common stock on August 15, 2022. These options were assumed by Black Titan in the Merger and exchanged for 1 Black Titan option for each Titan option.

F3: Options issued pursuant to Titan's 2015 Omnibus Equity Incentive Plan with an exercise price equal to the closing price of Titan's common stock on September 15, 2022. These options were assumed by Black Titan in the Merger and exchanged for 1 Black Titan option for each Titan option.

CapForce Inc.

Report date April 11, 2024 · Filed April 15, 2024

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	100,000	Reported balance After 2024-04-11 transaction · row 1 1 source row Row 1 · 2024-04-11 · Grant · Acquired 100,000 · Balance 100,000 F1: Shares of restricted stock issued pursuant to the 2015 Equity Incentive Plan of OpGen, Inc.

Filing footnotes · ownership attribution and instrument terms

F1: Shares of restricted stock issued pursuant to the 2015 Equity Incentive Plan of OpGen, Inc.

FiEE, Inc.

Report date September 26, 2024 · Filed October 02, 2024

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectBy: NLT Management and Asset Holding Company LTD	159,364	Reported balance After 2024-09-26 transaction · row 2 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 2 · 2024-09-26 · Grant · Acquired 159,364 · Balance 159,364 F1: Shares of restricted stock issued pursuant to the Non-Employee Directors Compensation Plan of Minim, Inc. F2: These shares are owned directly by NLT Management and Asset Holding Company LTD, an entity owned by the spouse of Mr. Ben-Tzvi in which Mr. Ben-Tzvi has a pecuniary interest.
Common StockSEC Table I · non-derivative	Direct	25,000	Reported balance Holding disclosure · report date 2024-09-26 · row 1 Holding and transaction disclosures are not merged. 1 source row Row 1 · Balance 25,000

Filing footnotes · ownership attribution and instrument terms

F1: Shares of restricted stock issued pursuant to the Non-Employee Directors Compensation Plan of Minim, Inc.

F2: These shares are owned directly by NLT Management and Asset Holding Company LTD, an entity owned by the spouse of Mr. Ben-Tzvi in which Mr. Ben-Tzvi has a pecuniary interest.

Indaptus Therapeutics, Inc.

Report date December 23, 2025 · Filed January 23, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	25,100	Reported balance After 2026-01-20 transaction · row 1 Account or security details depend on footnotes; rows are not merged. 1 source row Row 1 · 2026-01-20 · Grant · Acquired 25,000 · Balance 25,100 F1: The Reporting Person acquired 25,000 shares of restricted common stock of the Issuer pursuant to a consulting agreement dated January 20, 2026, which shares vested 100% upon grant. F2: Includes 100 shares of common stock of the Issuer held in a Roth IRA.
Option to Buy Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $1.95 · Expires 2035-12-23	Direct	25,000	Reported balance After 2025-12-23 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2025-12-23 · Grant · Acquired 25,000 · Balance 25,000 F3: The Reporting Person acquired options to purchase 25,000 shares of common stock pursuant to the Issuer's non-employee director compensation program. The stock options vest over three years commencing from the date of grant in equal quarterly installments subject to continued service on the Board through each vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: The Reporting Person acquired 25,000 shares of restricted common stock of the Issuer pursuant to a consulting agreement dated January 20, 2026, which shares vested 100% upon grant.

F2: Includes 100 shares of common stock of the Issuer held in a Roth IRA.

F3: The Reporting Person acquired options to purchase 25,000 shares of common stock pursuant to the Issuer's non-employee director compensation program. The stock options vest over three years commencing from the date of grant in equal quarterly installments subject to continued service on the Board through each vesting date.

LQR House Inc.

Report date October 16, 2024 · Filed October 23, 2024

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	0	Reported balance Holding disclosure · report date 2024-10-16 · row 1 Holding and transaction disclosures are not merged. 1 source row Row 1 · Balance 0 F1: No securities are beneficially owned.

Filing footnotes · ownership attribution and instrument terms

F1: No securities are beneficially owned.

Quantum Cyber N.V.

Report date July 22, 2026 · Filed August 06, 2026 · Amendment

Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Ordinary SharesSEC Table I · non-derivative	Direct	252,000	Reported balance After 2026-07-22 transaction · row 1 Amendment: may correct only part of an earlier disclosure. 1 source row Row 1 · 2026-07-22 · Grant · Acquired 112,859 · Balance 252,000 F1: The purpose of this Form 4/A is to correct (i) the date of the reported transaction, (ii) the quantity of securities acquired by the Reporting Person, and (iii) the quantity of securities beneficially owned by the Reporting Person following the reported transaction.

Filing footnotes · ownership attribution and instrument terms

F1: The purpose of this Form 4/A is to correct (i) the date of the reported transaction, (ii) the quantity of securities acquired by the Reporting Person, and (iii) the quantity of securities beneficially owned by the Reporting Person following the reported transaction.

TITAN PHARMACEUTICALS INC

Report date October 01, 2025 · Filed October 08, 2025

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2025-10-01 transaction · row 1 1 source row Row 1 · 2025-10-01 · Disposition to issuer · Disposed 3,313 · Balance 0 F1: Disposed of pursuant to the Merger and Contribution and Share Exchange Agreement, dated as of August 19, 2024 (the "Merger Agreement"), by and among Titan Pharmaceuticals, Inc. ("Titan"), Black Titan Corporation ("Black Titan"), TTNP Merger Sub, Inc., a direct wholly owned subsidiary of Black Titan ("Merger Sub") and TalenTec Sdn. Bhd, in exchange for 1 ordinary share of Black Titan common stock for each share of Titan common stock on the effective date of the merger (the "Merger").
Option to Purchase Common StockSEC Table II · derivative / convertible security	Direct	Reported balance After 2025-10-01 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2025-10-01 · Disposition to issuer · Disposed 1,250 · Balance 0 F2: Options issued pursuant to Titan's 2015 Omnibus Equity Incentive Plan with an exercise price equal to the closing price of Titan's common stock on August 15, 2022. These options were assumed by Black Titan in the Merger and exchanged for 1 Black Titan option for each Titan option.
Option to Purchase Common StockSEC Table II · derivative / convertible security	Direct	Reported balance After 2025-10-01 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2025-10-01 · Disposition to issuer · Disposed 5,000 · Balance 0 F2: Options issued pursuant to Titan's 2015 Omnibus Equity Incentive Plan with an exercise price equal to the closing price of Titan's common stock on August 15, 2022. These options were assumed by Black Titan in the Merger and exchanged for 1 Black Titan option for each Titan option. F3: Options issued pursuant to Titan's 2015 Omnibus Equity Incentive Plan with an exercise price equal to the closing price of Titan's common stock on September 15, 2022. These options were assumed by Black Titan in the Merger and exchanged for 1 Black Titan option for each Titan option.

Filing footnotes · ownership attribution and instrument terms

F1: Disposed of pursuant to the Merger and Contribution and Share Exchange Agreement, dated as of August 19, 2024 (the "Merger Agreement"), by and among Titan Pharmaceuticals, Inc. ("Titan"), Black Titan Corporation ("Black Titan"), TTNP Merger Sub, Inc., a direct wholly owned subsidiary of Black Titan ("Merger Sub") and TalenTec Sdn. Bhd, in exchange for 1 ordinary share of Black Titan common stock for each share of Titan common stock on the effective date of the merger (the "Merger").

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
July 31, 2026 Filed Aug 6, 2026 01:35 UTC	Quantum Cyber N.V. QUCY · Entity 6633	GrantOrdinary Shares	112,259	$0.00	$0.00	Disclosure SEC source: 0001213900-26-085872 · ownership.xml · nonDerivative · entry 1 Ben-Tzvi Avraham · CIK 0001944721 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 251,400 Read SEC document
July 22, 2026 Filed Aug 6, 2026 23:51 UTC Amendment	Quantum Cyber N.V. QUCY · Entity 6633	GrantOrdinary Shares	112,859	$0.00	$0.00	Disclosure SEC source: 0001213900-26-086310 · ownership.xml · nonDerivative · entry 1 Ben-Tzvi Avraham · CIK 0001944721 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 252,000 F1 · date: The purpose of this Form 4/A is to correct (i) the date of the reported transaction, (ii) the quantity of securities acquired by the Reporting Person, and (iii) the quantity of securities beneficially owned by the Reporting Person following the reported transaction. F1 · shares: The purpose of this Form 4/A is to correct (i) the date of the reported transaction, (ii) the quantity of securities acquired by the Reporting Person, and (iii) the quantity of securities beneficially owned by the Reporting Person following the reported transaction. F1 · balance_after: The purpose of this Form 4/A is to correct (i) the date of the reported transaction, (ii) the quantity of securities acquired by the Reporting Person, and (iii) the quantity of securities beneficially owned by the Reporting Person following the reported transaction. Read SEC document
May 08, 2026 Filed May 26, 2026 22:12 UTC	Quantum Cyber N.V. MYNZ · Entity 6633	GrantOrdinary Shares	137,141	$0.00	$0.00	Disclosure SEC source: 0001213900-26-061129 · ownership.xml · nonDerivative · entry 1 Ben-Tzvi Avraham · CIK 0001944721 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 139,141 Read SEC document
January 20, 2026 Filed Jan 23, 2026 02:57 UTC	Indaptus Therapeutics, Inc. INDP · Entity 6530	GrantCommon Stock	25,000	$0.00	$0.00	Disclosure SEC source: 0001493152-26-003293 · ownership.xml · nonDerivative · entry 1 Ben-Tzvi Avraham · CIK 0001944721 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,100 F1 · price: The Reporting Person acquired 25,000 shares of restricted common stock of the Issuer pursuant to a consulting agreement dated January 20, 2026, which shares vested 100% upon grant. F2 · balance_after: Includes 100 shares of common stock of the Issuer held in a Roth IRA. Read SEC document
December 23, 2025 Filed Jan 23, 2026 02:57 UTC	Indaptus Therapeutics, Inc. INDP · Entity 6530	GrantOption to Buy Common Stock · Derivative	25,000	$0.00 Strike: $1.95	$0.00	Disclosure SEC source: 0001493152-26-003293 · ownership.xml · derivative · entry 2 Ben-Tzvi Avraham · CIK 0001944721 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2035-12-23 F3 · price: The Reporting Person acquired options to purchase 25,000 shares of common stock pursuant to the Issuer's non-employee director compensation program. The stock options vest over three years commencing from the date of grant in equal quarterly installments subject to continued service on the Board through each vesting date. F3 · derivative.exercise_date: The Reporting Person acquired options to purchase 25,000 shares of common stock pursuant to the Issuer's non-employee director compensation program. The stock options vest over three years commencing from the date of grant in equal quarterly installments subject to continued service on the Board through each vesting date. Read SEC document
October 01, 2025 Filed Oct 8, 2025 20:21 UTC	TITAN PHARMACEUTICALS INC TTNP · Entity 74432	Disposition to issuerOption to Purchase Common Stock · Derivative	5,000	Not disclosed	Not disclosed	Disclosure SEC source: 0000921895-25-002721 · form413531003_10082025.xml · derivative · entry 3 Ben-Tzvi Avraham · CIK 0001944721 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires not disclosed F2 · derivative.exercise_price: Options issued pursuant to Titan's 2015 Omnibus Equity Incentive Plan with an exercise price equal to the closing price of Titan's common stock on August 15, 2022. These options were assumed by Black Titan in the Merger and exchanged for 1 Black Titan option for each Titan option. F3 · price: Options issued pursuant to Titan's 2015 Omnibus Equity Incentive Plan with an exercise price equal to the closing price of Titan's common stock on September 15, 2022. These options were assumed by Black Titan in the Merger and exchanged for 1 Black Titan option for each Titan option. F3 · derivative.exercise_date: Options issued pursuant to Titan's 2015 Omnibus Equity Incentive Plan with an exercise price equal to the closing price of Titan's common stock on September 15, 2022. These options were assumed by Black Titan in the Merger and exchanged for 1 Black Titan option for each Titan option. F3 · derivative.expiration_date: Options issued pursuant to Titan's 2015 Omnibus Equity Incentive Plan with an exercise price equal to the closing price of Titan's common stock on September 15, 2022. These options were assumed by Black Titan in the Merger and exchanged for 1 Black Titan option for each Titan option. Read SEC document
October 01, 2025 Filed Oct 8, 2025 20:21 UTC	TITAN PHARMACEUTICALS INC TTNP · Entity 74432	Disposition to issuerOption to Purchase Common Stock · Derivative	1,250	Not disclosed	Not disclosed	Disclosure SEC source: 0000921895-25-002721 · form413531003_10082025.xml · derivative · entry 2 Ben-Tzvi Avraham · CIK 0001944721 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,250 shares Expires not disclosed F2 · derivative.exercise_price: Options issued pursuant to Titan's 2015 Omnibus Equity Incentive Plan with an exercise price equal to the closing price of Titan's common stock on August 15, 2022. These options were assumed by Black Titan in the Merger and exchanged for 1 Black Titan option for each Titan option. F2 · price: Options issued pursuant to Titan's 2015 Omnibus Equity Incentive Plan with an exercise price equal to the closing price of Titan's common stock on August 15, 2022. These options were assumed by Black Titan in the Merger and exchanged for 1 Black Titan option for each Titan option. F2 · derivative.exercise_date: Options issued pursuant to Titan's 2015 Omnibus Equity Incentive Plan with an exercise price equal to the closing price of Titan's common stock on August 15, 2022. These options were assumed by Black Titan in the Merger and exchanged for 1 Black Titan option for each Titan option. F2 · derivative.expiration_date: Options issued pursuant to Titan's 2015 Omnibus Equity Incentive Plan with an exercise price equal to the closing price of Titan's common stock on August 15, 2022. These options were assumed by Black Titan in the Merger and exchanged for 1 Black Titan option for each Titan option. Read SEC document
October 01, 2025 Filed Oct 8, 2025 20:21 UTC	TITAN PHARMACEUTICALS INC TTNP · Entity 74432	Disposition to issuerCommon Stock	3,313	Not disclosed	Not disclosed	Disclosure SEC source: 0000921895-25-002721 · form413531003_10082025.xml · nonDerivative · entry 1 Ben-Tzvi Avraham · CIK 0001944721 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · price: Disposed of pursuant to the Merger and Contribution and Share Exchange Agreement, dated as of August 19, 2024 (the "Merger Agreement"), by and among Titan Pharmaceuticals, Inc. ("Titan"), Black Titan Corporation ("Black Titan"), TTNP Merger Sub, Inc., a direct wholly owned subsidiary of Black Titan ("Merger Sub") and TalenTec Sdn. Bhd, in exchange for 1 ordinary share of Black Titan common stock for each share of Titan common stock on the effective date of the merger (the "Merger"). Read SEC document
February 26, 2025 Filed Feb 28, 2025 21:47 UTC	Bio Green Med Solution, Inc. CYCC · Entity 8225	GrantNon-Qualified Stock Option (Right to Buy) · Derivative	700,000	$0.00 Strike: $0.33	$0.00	Disclosure SEC source: 0000921895-25-000650 · form412227019ben_02282025.xml · derivative · entry 1 Ben-Tzvi Avraham · CIK 0001944721 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 700,000 Underlying: Common Stock · 700,000 shares Expires 2035-02-26 F1 · price: On February 26, 2025 (the "Grant Date"), the Reporting Person was granted 700,000 Non-Qualified Stock Options to purchased shares of common stock (the "Common Stock") of Cyclacel Pharmaceuticals, Inc. (the "Company") in consideration of his services as a director of the Company. The option grant became exercisable on the Grant Date. F1 · derivative.exercise_date: On February 26, 2025 (the "Grant Date"), the Reporting Person was granted 700,000 Non-Qualified Stock Options to purchased shares of common stock (the "Common Stock") of Cyclacel Pharmaceuticals, Inc. (the "Company") in consideration of his services as a director of the Company. The option grant became exercisable on the Grant Date. Read SEC document
September 26, 2024 Filed Oct 2, 2024 00:31 UTC	FiEE, Inc. MINM · Entity 7395	GrantCommon Stock	159,364	Not disclosed	Not disclosed	Disclosure SEC source: 0000921895-24-002201 · form412227016ben_10012024.xml · nonDerivative · entry 2 Ben-Tzvi Avraham · CIK 0001944721 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By: NLT Management and Asset Holding Company LTD Disclosed balance after: 159,364 F1 · price: Shares of restricted stock issued pursuant to the Non-Employee Directors Compensation Plan of Minim, Inc. F2 · ownership.nature: These shares are owned directly by NLT Management and Asset Holding Company LTD, an entity owned by the spouse of Mr. Ben-Tzvi in which Mr. Ben-Tzvi has a pecuniary interest. Read SEC document
April 11, 2024 Filed Apr 15, 2024 13:07 UTC	CapForce Inc. OPGN · Entity 9776	GrantCommon Stock	100,000	Not disclosed	Not disclosed	Disclosure SEC source: 0000921895-24-000834 · form412227017ben_04122024.xml · nonDerivative · entry 1 Ben-Tzvi Avraham · CIK 0001944721 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 F1 · price: Shares of restricted stock issued pursuant to the 2015 Equity Incentive Plan of OpGen, Inc. Read SEC document
January 22, 2024 Filed Jan 24, 2024 22:09 UTC	FiEE, Inc. MINM · Entity 7395	GrantCommon Stock	25,000	Not disclosed	Not disclosed	Disclosure SEC source: 0000921895-24-000126 · form412227016ben_01242024.xml · nonDerivative · entry 1 Ben-Tzvi Avraham · CIK 0001944721 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 F1 · price: Shares of restricted stock issued pursuant to the Non-Employee Directors Compensation Plan of Minim, Inc. Read SEC document
October 25, 2023 Filed Oct 26, 2023 16:23 UTC	TITAN PHARMACEUTICALS INC TTNP · Entity 74432	GrantCommon Stock	16,250	$0.00	$0.00	Disclosure SEC source: 0000921895-23-002392 · form413531002ben_10262023.xml · nonDerivative · entry 1 Ben-Tzvi Avraham · CIK 0001944721 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 66,250 F1 · shares: The shares reported in this transaction represent Unrestricted Stock Awards pursuant to the Issuer's Fourth Amended and Restated 2015 Omnibus Equity Incentive Plan that vested immediately on the date of grant. Read SEC document
July 26, 2023 Filed Jul 31, 2023 19:38 UTC	TITAN PHARMACEUTICALS INC TTNP · Entity 74432	GrantCommon Stock	50,000	$0.00	$0.00	Disclosure SEC source: 0000921895-23-001765 · form413531ben_07282023.xml · nonDerivative · entry 1 Ben-Tzvi Avraham · CIK 0001944721 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 F1 · shares: The shares reported in this transaction represent Unrestricted Stock Awards pursuant to the Issuer's Fourth Amended and Restated 2015 Omnibus Equity Incentive Plan that vested immediately on the date of grant. Read SEC document
June 29, 2023 Filed Jul 31, 2023 19:38 UTC	TITAN PHARMACEUTICALS INC TTNP · Entity 74432	GrantOption to Purchase Common Stock · Derivative	100,000	$0.00 Strike: $1.31	$0.00	Disclosure SEC source: 0000921895-23-001765 · form413531ben_07282023.xml · derivative · entry 3 Ben-Tzvi Avraham · CIK 0001944721 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2032-09-15 F3 · derivative.exercise_price: The options were approved by the Issuer's Board of Directors on September 15, 2022. The options were conditioned on the approval by the Issuer's stockholders of an increase in the number of shares available for issuance under the 2015 Omnibus Equity Incentive Plan, which approval occurred on June 29, 2023. The exercise price of the options is equal to the closing price of the Issuer's common stock on September 15, 2022. F3 · date: The options were approved by the Issuer's Board of Directors on September 15, 2022. The options were conditioned on the approval by the Issuer's stockholders of an increase in the number of shares available for issuance under the 2015 Omnibus Equity Incentive Plan, which approval occurred on June 29, 2023. The exercise price of the options is equal to the closing price of the Issuer's common stock on September 15, 2022. F3 · derivative.exercise_date: The options were approved by the Issuer's Board of Directors on September 15, 2022. The options were conditioned on the approval by the Issuer's stockholders of an increase in the number of shares available for issuance under the 2015 Omnibus Equity Incentive Plan, which approval occurred on June 29, 2023. The exercise price of the options is equal to the closing price of the Issuer's common stock on September 15, 2022. Read SEC document
June 29, 2023 Filed Jul 31, 2023 19:38 UTC	TITAN PHARMACEUTICALS INC TTNP · Entity 74432	GrantOption to Purchase Common Stock · Derivative	25,000	$0.00 Strike: $1.52	$0.00	Disclosure SEC source: 0000921895-23-001765 · form413531ben_07282023.xml · derivative · entry 2 Ben-Tzvi Avraham · CIK 0001944721 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2032-08-15 F2 · derivative.exercise_price: The options were approved by the Issuer's Board of Directors on August 15, 2022. The options were conditioned on the approval by the Issuer's stockholders of an increase in the number of shares available for issuance under the 2015 Omnibus Equity Incentive Plan, which approval occurred on June 29, 2023. The exercise price of the options is equal to the closing price of the Issuer's common stock on August 15, 2022. F2 · date: The options were approved by the Issuer's Board of Directors on August 15, 2022. The options were conditioned on the approval by the Issuer's stockholders of an increase in the number of shares available for issuance under the 2015 Omnibus Equity Incentive Plan, which approval occurred on June 29, 2023. The exercise price of the options is equal to the closing price of the Issuer's common stock on August 15, 2022. F2 · derivative.exercise_date: The options were approved by the Issuer's Board of Directors on August 15, 2022. The options were conditioned on the approval by the Issuer's stockholders of an increase in the number of shares available for issuance under the 2015 Omnibus Equity Incentive Plan, which approval occurred on June 29, 2023. The exercise price of the options is equal to the closing price of the Issuer's common stock on August 15, 2022. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.